Cardiac AI: How CMS Fuels Billion-Dollar ROI for Investors

AI in healthcare, especially for cardiology, is finally moving past the hype and starting to show a real financial impact. The reason isn’t just better algorithms. It’s that the Centers for Medicare and Medicaid Services (CMS) is aggressively changing how it pays for care. These new value-based reimbursement policies are turning AI programs from a “nice-to-have” science project into a core strategy for any hospital that wants to stay solvent. If you’re an investor, you absolutely have to understand how clinical results get turned into actual dollars through these policies, because that’s the only way to figure out the real ROI on any of this tech.

The Policy Imperative: How CMS is Redefining AI’s Value Proposition

The old fee-for-service model was a terrible environment for preventative AI, because it paid for volume, not value. Why invest in a tool that prevents a hospital stay when you get paid for that stay? But CMS has completely upended the board with its shift to value-based care models like Accountable Care Organizations (ACOs) and bundled payments. Now, health systems are on the hook financially for patient outcomes, readmissions, and total cost of care, which happens to be exactly what a well-designed AI is good at improving. As one venture partner in digital health told me, “The policy implications are no longer a side note. They’re the main act.” He’s right. When CMS creates a new billing code or adjusts an old one for a new technology, a market is born overnight. For cardiac AI, any tool that can prove it shortens a hospital stay, prevents a heart attack, or makes a diagnosis cheaper is suddenly generating cash that shows up on a P&L. This proves that ROI isn’t some fixed number. Its value depends entirely on whether it fits into one of these new value-based frameworks and has a clear path to getting paid.

Viz.ai and Tempus AI: Working through the Value-Based Field

Look at a company like Viz.ai or Tempus AI to see how this works in the real world. They both built their platforms with one eye on the clinical problem and the other on the reimbursement paperwork.

Viz.ai: Expediting Stroke Care, Reducing Costs

Viz.ai which pulled in a $100 million Series D to hit a $1.2 billion valuation with backers like Tiger Global, is a perfect case study in how AI creates ROI by shaving minutes off critical timelines. Their platform uses AI to read brain scans for signs of a major stroke (a large vessel occlusion), and if it finds one, it immediately pings the stroke specialist’s phone. No waiting for a radiologist to read the scan and then for someone to page the right doctor. The time to treatment plummets. A policy expert I spoke with put it perfectly: “By reducing the time to thrombectomy, they’re improving patient outcomes and reducing disability, and they’re also cutting the length of hospital stays and the associated costs of long-term care. These are metrics directly tied to CMS’s objectives for quality and efficiency.” Their Viz.ai FDA clearances for stroke detection give them the regulatory stamp of approval they need to get paid, and their metrics on shorter treatment times are a direct line to savings for health systems operating under risk-sharing agreements.

Tempus AI: Precision Medicine and Data Integration

Then there’s Tempus AI, which hit a $6.1 billion valuation at its IPO. They’re playing a different game, building up a massive library of clinical and molecular data (including genomics) to generate insights for truly personal treatment plans. For a cardiologist, this could mean getting an alert that your patient has a hidden genetic risk for heart failure, or getting data that shows they won’t respond well to a common blood pressure med, letting you pick a better one from the start. As another expert venture partner commented, “Tempus AI’s value proposition in cardiovascular health lies in its ability to stratify patient risk and guide precision interventions. Under value-based models, preventing adverse cardiac events or tailoring therapies to avoid ineffective treatments directly impacts costs and quality metrics.” Their real strength is what he called their “data moat” [🔵], by integrating data from tons of sources, they’ve built an asset that’s incredibly hard for anyone else to copy, which they use to train AI that can make these precise predictions. The company’s web of Tempus AI clinical data partnerships is the bedrock of this strategy, allowing them to build tools that spot at-risk patients early and fine-tune their care, which leads to better health and lower spending.

The Pitfalls: A Cautionary Tale from Olive AI

For every Viz.ai, there’s a cautionary tale, and Olive AI is the big one. The company raised an incredible $902 million from investors including Tiger Global before it completely imploded. Its mission, automating the mountains of administrative work in healthcare, sounded great on a Powerpoint slide. But in practice, customers struggled to see a clear, measurable ROI that made the high cost and painful implementation worthwhile. “Olive AI’s trajectory illustrates that simply having AI isn’t enough,” one digital health investor states. “The market demands clear, undeniable ROI that integrates with existing workflows and, importantly, aligns with how healthcare providers are reimbursed. If your AI solution doesn’t directly contribute to better patient outcomes or demonstrable cost reductions that are recognized by payers like CMS, its financial viability is tenuous, regardless of the technology’s sophistication.” What’s the difference between a success and a failure? Just look at Hello Heart, which can point to peer-reviewed studies showing a concrete $1,800 in savings per member and a 47% drop in inpatient admissions. If you can’t show numbers like that, you’re in trouble.

Audience Takeaway: Strategic Investment in Policy-Aligned AI

So if you’re an investor or VC looking at this space, the lesson is simple. Forget the slick demo and the talk about algorithms. Your due diligence should focus on the boring stuff: a company’s deep understanding of federal reimbursement codes and value-based care. Does the solution have a path to a CPT code [🔵]? Has it navigated the FDA with a 510(k) [🔵] or De Novo Classification [🔵]? Can the company show you real-world evidence (RWE) [🔵] that proves it saves money in ways CMS actually recognizes? You need to be investing in platforms that can draw a straight line from their product to a health system’s bottom line using metrics that payers care about. A company that talks about GMLP (Good Machine Learning Practice) [🟡] and its QMS / ISO 13485 [🟡] quality system is showing you it understands the regulatory and quality hurdles, which is a massive de-risking signal. The old startup mantra of “build it and they will come” is dead in healthcare. The new rule is: if you can’t get it reimbursed, they won’t come. CMS guidelines on digital health reimbursement

Methodology Note

This analysis is based on interviews with several venture partners and policy experts who work in digital health every day. We combined their on-the-ground perspectives with public information on company funding, regulatory status, and CMS’s own value-based care guidelines to get a clear picture of what’s driving ROI in cardiovascular AI.